Author:
Lai Zhicheng,Xu Yujie,Chen Hailong,Kan Anna,Wu Zichao,Li Qijiong,Lu Minqiang,Wei Wei,Zhang Yao-Jun,Chen Minshan,He Minke,Xu Li,Shi Ming
Reference25 articles.
1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries;H Sung;CA Cancer J Clin,2021
2. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma;R S Finn;N Engl J Med,2020
3. Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology;A B Benson;J Natl Compr Canc Netw,2021
4. Camrelizumab plus rivoceranib versus sorafenib as firstline therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label;S Qin;Lancet,2023
5. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study;Z Ren;The Lancet Oncology,2021